Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $559.34M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.84M
Average 1.43M
Returns on capital
Zevra Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
53.8%
avg 46.5%
ROIC
-1.7%
avg -100.5%
ROA
29.2%
avg -76.8%
Analysis
ROE is currently the strongest return metric at 53.8% versus its period average of 46.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Neil F. McFarlane | President, Chief Executive Officer & Director | USD 1.16M | 53 | 417.23K | 0.71% |
Joshua Schafer | Chief Commercial Officer | USD 766.07K | 54 | 62.28K | 0.11% |
Rahsaan W. Thompson | Chief Legal Officer, Secretary & Compliance Officer | USD 753.33K | 55 | — | — |
Adrian Quartel FFPM | Consultant | USD 705.13K | 65 | — | — |
Justin A. Renz | Chief Financial Officer & Treasurer | USD 704.07K | 54 | 0 | <0.01% |
Timothy J. Sangiovanni | Senior VP of Finance & Corporate Controller | — | 42 | 20.00K | 0.03% |
Gerald J. Orehostky | Senior Vice President of Regulatory Affairs & Quality | — | 59 | — | — |
Alison Peters | Chief People Officer | — | — | — | — |
Nichol L. Ochsner | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Tanya Hayden | Senior Vice President & Chief of Staff | — | 46 | — | — |
Christopher Lauderback | Senior Vice President of Manufacturing | — | 51 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$2.52M
Net Transaction Value
−$2.52M
Net selling
Most Active
Thompson Rahsaan
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 12, 26Oct 12, 2026 | McFarlane Neil F. Direct | Sell | $224.9K$224,948.00 |
| Aug 14, 26Aug 14, 2026 | Thompson Rahsaan Direct | Sell | $474.8K$474,774.45 |
| Aug 10, 26Aug 10, 2026 | Watton Corey Michael Direct | Sell | $138.4K$138,377.46 |
| Jun 22, 26Jun 22, 2026 | Thompson Rahsaan Direct | Sell | $438.3K$438,303.71 |
| May 11, 26May 11, 2026 | Thompson Rahsaan Direct | Sell | $20.3K$20,272.20 |
| Feb 9, 26Feb 9, 2026 | McFarlane Neil F. Direct | Sell | $125.2K$125,185.61 |
| Feb 3, 26Feb 3, 2026 | Sangiovanni Timothy J. Direct | Sell | $27.5K$27,548.10 |
| Feb 3, 26Feb 3, 2026 | Schafer Joshua Direct | Sell | $96.5K$96,500.25 |
| Feb 2, 26Feb 2, 2026 | McFarlane Neil F. Direct | Sell | $853.4K$853,425.30 |
| Jan 30, 26Jan 30, 2026 | Sangiovanni Timothy J. Direct | Sell | $15.4K$15,442.00 |
1–10 of 13
Summary
Insiders reported 0 buys worth $0.00 and 13 sells worth $2.52M over the last 12 months. That adds up to net selling of $2.52M. Thompson Rahsaan was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +10.0% (5yr)4 analysts |
| Revenue | N/A | N/A | +118.8% | +22.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | +8.4% (5yr)5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +118.8% over three years. Forward estimates point to Revenue at +22.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Zevra Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ZVRA's management, answered from reported figures.
Who manages ZVRA?
Zevra Therapeutics, Inc. (ZVRA) lists 11 active executives. The top listed executive is Timothy J. Sangiovanni, Senior VP of Finance & Corporate Controller.
Are ZVRA insiders buying or selling?
Recent insider activity shows net buying of $13.83M.
Continue the stock analysis
Jump to another research area for this company.